DHR - Danaher Corp P/S Multiple

Corporate company logo of Danaher Corporation Inc. (DHR)

High barriers to entry and stringent certification protect the business by locking laboratories into proprietary software. Danaher Corp. (DHR) is currently overcoming a post-pandemic slump in the biotech segment while anticipating a recovery in demand. Scalability is driven by the DBS system and the sale of consumables. The company's price-to-sales ratio clearly illustrates the valuation trend, where the value 6.40 captures this metric on the chart.

DHR Danaher Corp: P/S Multiple in the range 07/04/2022 - 11/14/2026

Danaher Corp (DHR) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart Danaher Corp|DHR - Consensus Target
- market capitalization statistics:
Market Capitalization Danaher|DHR - Total Company Value
- balance sheet equity data:
Accounting Value per Share Danaher|DHR - Book Capitalization|Market-to-Book Ratio danaher.com|DHR - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Danaher Corp.|DHR - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio danaher.com|DHR - Company Debts|Debts to Net Assets Danaher Corporation Inc.|DHR - Company Long-Term Debts|Company Short-Term Indebtedness Danaher|Quick Ratio danaher.com
- business earnings and investment ratios data:
DHR - Company Net Income|Net Profit Forecast Danaher Corp.|DHR - P/E Multiple|Forward P/E Multiple Danaher Corp|DHR - PEG Multiple|Business Value to Operating Income Before Depreciation Danaher Corporation Inc.|DHR - Operating profit EBITDA|Net earnings per one share for the last twelve months Danaher|DHR - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months danaher.com|DHR - Net earnings per share growth this year|Expected earnings per share trend next year Danaher Corp.
- issuer revenue and sales details:
DHR - Revenue and Sales Volume|Company Future Sales Volume Danaher Corporation|DHR - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Danaher
Fundamental company analysis:DHR, Danaher
Manufactured products of Danaher Corporation

Danaher Corp. serves as the benchmark in biomedicine, where the P/S ratio reflects the market value of each unit of revenue, allowing for an assessment of the premium paid for exceptional instrument quality and the business system. Analyzing the company's industry-average P/S helps investors filter out speculative bubbles by comparing current market capitalization with actual cash flows to determine a safe entry point into the asset.

Competing companies

Market Cap to Sales Volume ISRG|BD - Market Cap to Revenue|P/S Multiple STERIS Group STE|WST - Price-to-Revenue Ratio|Baxter International (BAX) - Market Cap to Revenue|Masimo Corp (MASI) - Price-to-Revenue Ratio|Market Cap to Revenue Stevanato Group|Price-to-Revenue Ratio Teleflex Incorporated|Price to Sales Merit Medical Corp MMSI|Price-to-Revenue Ratio Envista (NVST)|ICU Medical - Market Cap to Revenue Ratio|DENTSPLY SIRONA Inc. - Market Cap to Revenue|Market Cap to Sales Volume LMAT (LeMaitre Vascular Inc)|ATRC - Price-to-Revenue Ratio|Price-to-Revenue Coefficient STAAR Surgical Co STAA|NAGE: P/S Multiple|Price-to-Sales Ratio ZIMV (ZimVie Inc.)|Price-to-Revenue Ratio AngioDynamics Corp|Price to Sales Cerus Corp. CERS|Price-to-Revenue Ratio Teknova (TKNO)|Monogram Orthopedics Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Sharps Technology, Inc. STSS|P/S Multiple InfuSystem Holdings INFU|UTMD: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KRMD (KORU Medical)|NYXH: P/S Multiple|MBOT (Microbot Medical, Inc) - Price-to-Revenue Ratio|Market Cap to Revenue PDEX|ZTEK: Market Capitalization-to-Revenue Ratio|P/S Multiple ELUT|Milestone Scientific Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio NEXGEL, Inc. NXGL|Retractable Tech - Price-to-Revenue Ratio|harvardbioscience.com - P/S Multiple|FEMY (Femasys Inc.) - Market Cap to Revenue Ratio|MHUA: P/S Multiple|Predictive Oncology Corp - Market Capitalization-to-Revenue Ratio|CJMB (Callan JMB) - P/S Multiple|Price to Sales Atrion Corporation Inc. ATRI|P/S Multiple NURO